- Strengthen Europe´s competitiveness in lifescience innovation and healthcare in light of geopolitical challenges – impact on operating models, access to medicines, and drug development
- Safeguard competitive positioning by embedding the patient voice into drug development and commercial strategy to prove value with pricing pressures
Carlos Gallardo, Chairman and Chief Executive Officer, Almirall and VP, EFPIA
Camille Lancelot, Community Manager, IFPA
- As pricing pressure shifts cost and risk toward patients, what does that mean for patient engagement—and for access itself? Explore how engagement becomes as critical as reimbursement in determining uptake and outcomes
- With European launches becoming harder to make the math work, can today's go-to-market models keep up? Examine whether traditional launch models can scale sustainably amid tighter budgets and rising complexity
- With innovation globalizing and geopolitics growing less stable, what role will Europe play in the decade ahead? Assess how China's emergence as a biopharma innovation powerhouse challenges assumptions about where innovation originates and scales
Bill Coyle, Managing Principal - Europe, ZS
- Strengthen global rare disease innovation momentum by building upon established regulatory frameworks and addressing evolving EU policy considerations that impact investment
- Accelerate early therapeutic intervention through AI-powered diagnostic tools that improve detection accuracy and reduce time to treatment
- Advance health equity by building multistakeholder collaboration models that unite payers, providers, and industry to expand patient access
Marc Dunoyer, Chief Executive Officer, Alexion
Reuters hosts a conversation with Cooke - who oversees the evaluation, authorisation and monitoring of medicines for more than 440 million people – about the factors shaping Europe’s pharmaceutical landscape at a critical moment for global health. In a live broadcast interview, Cooke will discuss how the EMA is handling rapid scientific innovation and the need to balance patient safety and public trust and industry needs. She’ll also look at what’s next for medicines regulation, including digital health, real-world evidence, manufacturing resilience and the increasingly complex geopolitics of global supply chains.
Emer Cooke, Executive Director, The European Medicines Agency (EMA)
Maggie Fick, European Pharmaceuticals Industry Correspondent, Reuters
Â
This interview will be conducted under the Reuters Trust Principles
- Compound commercial performance over time by transforming CRM from a basic interface into an intelligence system that captures and leverages organisational memory as a strategic asset
- Drive context-aware engagement and automate commercial workflows at scale through AI agents that leverage collective data and intelligence
Stephen Wood, EMEA Regional Leader for Healthcare & Lifesciences, Microsoft
- Drive cross-functional excellence by dismantling silos through cross-functional insights and unified platforms that enable empowered teams to act faster
- Outpace competitors by strategically investing in AI tools at critical inflection points to automate workflows and accelerate time-to-market for innovation
Diana Medeiros Plácido, Chief Digital & Technology Officer, ViiV Healthcare
Chetak Buaria, VP, Global Commercial Operations, Merck
Tom Baker, SVP, Global Data, Technology, and Advisory Services, IQVIA
- Elevate your position as an HCP partner by deploying AI-powered digital platforms that facilitate more effective communication between HCPs and their patients
- Improve patient health outcomes and access to care by embedding personalised, user-friendly tools that connect patients to critical treatment information at the point of need
Philippe Pinton, SVP, Head, Global Research and Medical, Ferring Pharmaceuticals
Dr Dana Vigier, VP, GM Alexion France & BeLux, Alexion
Jean‑Philippe Plançon, Chairman of the Board and President, EPODIN (European Patients Organization for Dysimune & Inflammatory Neuropathies)
Sabine Louët, Founder & Chief Executive Officer, SciencePOD
- Transform fragmented data into accessible, high-quality strategic assets by implementing FAIR principles that ensure quality and scale across the enterprise
- Accelerate breakthrough outcomes from in silico research to supply chain optimization through secure-by-design platforms that enable confident adoption of autonomous agentic workflows
Ralf Schundelmeier, Head of Enterprise Data and Platforms, Boehringer Ingelheim
- Co-creation with patients is reshaping the way pharma companies define and design the ideal patient experience – move from assumption-led models to ones built on real-world needs and lived experience
- Ground the future of patient experience in the real world: explore specific disease area use cases where innovative design is making a measurable difference
Karima Siddiqui, Global Director Patient Health Excellence, Takeda
Daniel Leutenegger, Global Director Patient Health Excellence, Takeda
- Unlock a proven reform framework that reduces patient cost burden by 40–65% without manufacturer price cuts — redirecting market access strategy toward distribution and tax structures
- Immediate reform opportunities from 35-country research by identifying where distribution margin and VAT reform create the fastest, most durable affordability and patient access gains
Giovanny Leon, Chair, Medicines Affordability & Adherence Alliance
Simulate impact before deployment to de-risk channel mix, refine access pathways, and prioritise high-yield HCP engagement
Align global strategy with local execution through modular playbooks, clear governance, and co-ordinated field–digital actions
Optimise territories, incentives, and resource allocation in-cycle using real-time signals and next-best-action engines
Â
Fleur Gill, VP Sales & Partnerships - Global, Doceree
- Transform disconnected AI pilots into a governed, enterprise-wide operating model by deploying agentic orchestration across R&D, clinical development, and commercial operations
- Drive compounding enterprise value by executing a practical roadmap that converts isolated use cases into end-to-end agentic workflows with measurable, board-ready ROI
Johanna DeYoung, Global Industry Lead, Healthcare & Life Sciences, Slalom
- Deliver intelligent, agent-orchestrated PSPs to transform traditional support into autonomous, always-on care systems that proactively coordinate onboarding, drive adherence and respond to evolving patient needs in real time.
- Measure what matters by using real time data and connected analytics to link awareness, adherence, persistence, and patient experience, shifting focus from task volume to meaningful patient and business outcomes
Ihab Fakhouri, HLS GTM Lead, Salesforce
- Accelerate critical decision-making at key value inflection points by anticipating IRA, JCA, and MFN policy impacts on development pathways
- Transform commercialisation models and build integrated evidence strategies that demonstrate value across evolving healthcare systems through cross-functional capabilities
Â
Steve Mather, Joint Global Practice Lead, Strategy & Insight, Lumanity
- Accelerate innovation cycles and deliver ecosystem-wide value by embedding patient insights and visualising the journey from clinical trials to market
- Amplify patient outcomes by creating bidirectional HCP-patient communication channels that transform medical communications into insight-rich exchanges
Maria Galindo Perez, VP, Global Head of Publications, Bayer
Isabelle Lonjon-Domanec, VP, Clinical Medical Regulatory, Novo Nordisk
Samantha Scheer, Head of Global Medical Communications, Neurology & Immunology, Merck
Sarah Frazer, VP, Head of Medical Strategy, Real Chemistry
- Sustain trust at scale by proving stewardship and reviewing transparency metrics with advisory input each quarter
- Enable collaborative data ecosystems by investing in shared registries and quality standards, creating the foundation for outcome-based pricing and innovative reimbursement models
Meni Styliadou, VP Global Program Leader – Health Data Partnerships, Takeda
Moderator: Charlotte Brimacombe, Head of Pharma, Reuters Events
- Embed tested strategies for winning internal stakeholder support by presenting PSP business cases that connect patient-centric program design to measurable commercial outcomes and long-term brand differentiation
- Evaluate what successful PSPs actually deliver in practice through multi-stakeholder perspectives to create your actionable optimisation roadmap that balances patient needs, operational agility, and strategic business objectives
Sarah Mertens, Head of UCBCares & Patient Support Global, UCB
Ana Maria, Global Director, Patient Experience, Pfizer
Geoff Rollason, Patient/Patient Advocate
Moderator: Seth Ginsberg, Co-Founder & President, Global Healthy Living Foundation
- Drive pre-launch readiness by engaging with medical societies, government health agencies, and clinical communities to improve diagnostic rates, shape policy, and address unmet needs ahead of launch
- Optimise uptake during launch by deploying field-based teams to identify reimbursement barriers and co-create solutions with health authorities, insurers, and hospital systems at regional levels
Clara Rodriguez, Director, Market Access Oncology, Pfizer
Kemal Uca, VP, Head of Global Market Access & Pricing Cardiovascular Metabolism & Endocrinology and Fertility, Merck
Karen Lightning-Jones, Pricing, Reimbursement, Policy and Communications Lead, Roche
Moderator: Jonathan Elliott, Director of Content Development, Thomson Reuters
- Reshape operating models and commercial decision making by leveraging data, technology, and AI to drive strategic agility across in market brands
- Evolve commercial models for established brands to protect value and improve efficiency in dynamic market conditions
- Scale impact and optimise resource allocation through flexible outsourcing commercialisation approaches informed by real time data and peer insights
Brian Burgess, Director, International Business Development & Brand Outsourcing, IQVIA
Thomas Steffen, Principal, Strategy Consulting, IQVIA
Martin Bate, Head of HCP Engagement, IQVIA
At last year’s event, we introduced a bold blueprint for rewiring customer engagement with AI - a framework that illustrated how segmentation, targeting, omnichannel activation, content supply, and field execution could operate as a connected commercial and medical engagement ecosystem. This year, we shift from vision to reality, examining what has changed in the market, where organizations have made meaningful progress, where adoption has slowed, and what must evolve to unlock scaled, sustainable adoption and value. The workshop will:
- Explore advances emerging across areas like AI‑enabled and agentic sales operations
- Examine modernising end‑to‑end marketing and content supply
- Provide a practical view of how to evolve your field, marketing, and analytics capabilities in the year ahead
Priya Arora, EMEA Commercial AI and Data Lead, Deloitte
- An exclusive preview of new research will guide facilitated problem-solving that identifies where momentum breaks down and where to deploy practical solutions
- Accelerate execution by co-creating a Change Action Framework that prioritises CX challenges and aligns stakeholders on immediate next steps
- Identify measurements that capture true investment value and demonstrate impact across customer engagement initiatives
Dirk Szynka, Vice President Customer Experience, Inizio Engage International
Steph Plowright, Director of Strategy & Innovation, Nazaré
Greg Draper, Commercial Operations Director, Inizio Engage
This session is designed as an interactive experience, showing how teams can harness HCP behavioral intelligence via Inizio Evoke’s datalake in real time to sharpen targeting and drive activation.
Using Predictevâ„¢, our live intelligence platform, attendees will be able to ask direct questions and see immediate answers on HCP prescribing behaviors, emerging patient segments, and growth opportunities, bringing data to life in the moment.
Built on 75+ million hours of behavioral data, the platform surfaces audience mindsets, engagement triggers, and investment optimization opportunities across the treatment journey, enabling faster decisions, sharper targeting, and more confident investment decisions.
Niklas Ekman, Practice Lead, Product, Inizio Evoke
- Share common challenges in evidence planning and execution in today’s multi-market, multi-audience environment
- Examine industry readiness to move beyond static evidence plans and scale the effective use of digital and intelligent tools across functions & teams
- Explore how evidence strategies can be designed for uncertainty, including evolving TPPs, adaptable scientific and value narratives, and multiple HTA and access scenarios across markets
Gavin J. Outteridge, General Manager, Arysana
From AI Experiments to Commercial Impact: Building a Governed Agentic Platform That Accelerates Time from R&D to Product Launch
AI pilots are multiplying across pharma. Few are scaling. Even fewer are accelerating launch performance. Many organizations are layering AI onto fragmented systems, creating more noise and not better execution. This workshop will explore how pharmas can move from isolated AI experiments to a governed agentic commercial platform built for highly-regulated environments:
- Connect agent workflows to the KPIs that matter compressing timelines across the entire pharma value chain and turning operational gains into accelerated market transformation
- Build a self-improving platform where engagement data and user behaviour signals feed back into agent policies and targeting models — so every product development and launch makes the next one faster and smarter
- Embed governance as an accelerant, leaving with a practical human-in-the-loop framework that creates auditable, continuously improving value chain operations without sacrificing speedÂ
Rohit Dayama, Global Client Partner & Life Sciences Market Lead, Cognizant
Vishal Mehta, Global Head of Life Sciences, ServiceNow
• Co-design frameworks that give patient advocates and patients defined decision-making roles — not just advisory ones — across digital patient experience design, PSP development, and evidence generation, ensuring the patient voice shapes strategy rather than validates it after the fact
• Build transparent partnerships and establish clean guidelines that allow pharma executives and patient advocates to demonstrate impact to their respective stakeholders – and to each other
Moderator: Mark Duman, Patient Engagement Pioneer, MD Healthcare
- Expose real launch blockers using your own pharma use cases - not hypotheticals
- Break cross‑functional silos fast by aligning medical, commercial and market access around shared AI insights
- Shape AI‑powered launch moves that elevate HCP engagement and streamline compliant execution
- Create a standout concept that accelerates brand impact and is ready to socialize with your teams
Krystian Jablonski, Director, Data & AI Strategic Solutions and Poland Site Leader, Lingaro
Ivanka Vankova, Life Sciences Lead, Commercial Analytics, Lingaro
Build AI literacy through structured capability programs that teach reps to interpret predictive HCP signals and prioritise outreach to increase meeting acceptance rates and message receptivity
Embed next-best-action recommendations directly into CRM and mobile tools to deliver timely, personalised content for every HCP interaction that accelerates prescribing behaviour
Arun Nair, Head of International Commercial - Data & Analytics (IT), Gilead
- Improve journey consistency by unifying profiles and hierarchies – such as customer matching and product lists – across commercial, medical, and access teams
- Raise relevance by governing stewardship and quality with business ownership and a shared data catalog
Shreenivasa Rajanala, Global Head of Data Analytics and AI Foundations, Global Commercialisation, Bayer
- Generate continuous patient outcome and behavioural insights from digital health tools and platforms that strengthen HCP capabilities
- Enhance HCP engagement through digital health outputs that address real world information gaps with patient behavior analytics
Richard Cassidy, SVP and President of the Rx+ Business Accelerator, Astellas
- Accelerate evidence-based launch decisions by integrating AI capabilities that validate differentiation and stress-test value assumptions before market entry
- Strengthen global pricing defensibility by bridging development and commercialisation with MFN-ready access strategies and evidence generation
Daniel Zolnierz, VP New Product Planning, Neurology & Immunology, Merck
Keir Woods, VP, Global Value Demonstration, Market Access & Pricing (GVAP) - Oncology, Merck
- Accelerate strategic decision-making by leveraging exclusive 2026 research findings on field excellence priorities, critical trade-offs and emerging themes
- Drive cross-functional transformation across Sales, Marketing, Medical and Market Access by converting research insights into actionable field excellence strategies tailored to your business objectives
Steph Plowright, Director of Strategy & Innovation, Nazaré, part of Inizio Engage
Wil Procter, Director of Strategy & Innovation, Nazaré, part of Inizio Engage
- Drive measurable field force effectiveness by closing the gap between CRM data generation and HCP-facing execution through harmonised, real-time data pipelines
- Embed next-best-action intelligence directly into field workflows to accelerate commercial decision-making at the point of engagement
Â
Jonathan Vitale, Business Development Lead, Trueblue
Hartmann Estruch, Commercial Excellence & Customer Centricity Iberia Director, Zambon S.A.U.
• Move beyond pilots: how pharma, hospitals and startups can co-create digital solutions that improve patient follow-up
• Turn innovation into adoption: lessons learned in transferring innovation into real clinical pathways
Omar Al-Nehlawi Valverde, Head of Innovation & Patient Centric Solutions, Amgen
- Plan smarter and align faster with AI to achieve launch precision and effectiveness
- Execute intelligently to drive day-one impact and sustained value
Sarah Rickwood, VP, Thought Leadership, IQVIA
Natalie Harb, VP, Offering Development – Launch Excellence, IQVIA
Peter Thomsen, Global Assoc. Launch Director, Obesity, Novo Nordisk
- Equip field teams to translate real-time HCP signals such as channel-preference shifts and content engagement patterns into prioritised actions that increase meeting conversion rates and accelerate prescribing decisions
- Align upskilling programmes to commercial KPIs that validate field effectiveness, including HCP engagement depth, message recall, and territory-level script growth to demonstrate measurable ROI
Chetak Buaria, VP, Global Commercial Operations, Merck
Philippe Guisset, Business Unit Director, Alfasigma
Dr. Konstanze Wagner, Executive Director Strategy & Operations, Bristol Myers Squibb Germany
Michael Zaiac, Head of Medical Affairs Oncology EUCAN, Daiichi Sankyo
Moderator: Sam Rolfe, Sales Director, Exeevo
- Accelerate initiatives by defining data owners, access paths, decision rights and approval workflows for priority customer data sets
- Build confidence by tracking policy adherence and resolving issues in monthly cross‑functional data councils to daily commercial activities
- Transform customer data into compelling narratives that engage audiences emotionally while delivering quantifiable business results
Chris Duarte, Head of Data, Analytics and Insight, ViiV Healthcare
Moderator: Marta Diaz, Head of Data Strategy, Platform and Governance, Novartis
- Implement patient data education frameworks that directly increase consent rates and data-sharing participation to unlock high-quality RWE for decision-makers and product differentiation
- Quantify the ROI of digital health initiatives by tracking conversion metrics from education touchpoints to digital health enrolment and improved medication adherence, thereby enhancing patient lifetime value across portfolios
Grégoire Guillet, Chief Business & Value Officer - Digital Factory, Servier
Johannes Munding, Director Patient Experience, Novartis
Patricia Ripoll, Founder & President, Fundación
David Braun, Head of Commercial Operations and Customer Engagement Global Digital Health, Merck
Moderator: Seth Ginsberg, Co-Founder & President, Global Healthy Living Foundation
- Maximise global revenue via building adaptive launch frameworks that respond to market complexity
- Optimise product value realisation across diverse markets by exploring strategic sequencing approaches and leverage analytics to inform long-term commercial decisions
Michele Siccardi, Executive Director, Head of International (ex US) Insights & Analytics, CSL
Ulf Staginnus, VP International Market Access & Pricing, Blueprint Medicines (A Sanofi Company)
Silvia Maeso, VP, Global Market Access, Health Economics, Pricing and HTA, Almirall
Moderator: Gerardo Martinez, Senior Director, Global Market Access - Pipeline (Immunology & Rare Disease), CSL
Question the foundations. Accelerate what matters. Shape a future of work that works for everyone.
- Drive sustainable transformation by establishing identity, confidence and psychological safety as core infrastructure for AI adoption
- Deliver representative outcomes by proactively dismantling bias in AI design and embedding inclusion as a strategic imperative
- Accelerate organisation-wide capability by cultivating leadership practices that inspire experimentation
Dagmar Albers, VP EMEA, Healthcare Businesswomen's Association
Sarah Dancy Blackburn, Director of Value EMEA, Healthcare Businesswomen's Association
- Identify the optimal moments and channels to engage HCPs by mapping the customer journey against strategic business objectives, driving seamless engagement across relevant platforms for your organisation
- Foster meaningful connections with HCPs through intelligent orchestration that personalises interactions and responds to individual needs, building rapport and trust
Sander Ruitenberg, Senior Director, Omnichannel Engagement, CSLÂ
- Architect and scale unified, governed data platforms that enable secure, interoperable, and AI-ready foundations for R&D, diagnostics, and commercial use cases
- Accelerate analytics and AI adoption through self-service enablement and platform-as-a-product capabilities, ensuring teams deliver insights faster while maintaining compliance and cost efficiency
Kishan Rees, Senior Director Video & Media Content Strategy, Bayer
Tom Keith-Welsh, Client Partner, Bayer
- Recruit and partner with KOLs, HCPs and patient organisations to raise digital health confidence and value
- Revolutionise HCP perception and scale compliant promotion by strategically positioning influential digital health leaders as product champions
Emre Ozcan, SVP Global Head of Digital Health & Devices, Merck
Moderator: Seth Ginsberg, Co-Founder & President, Global Healthy Living FoundationÂ
- Navigate the shift from absolute proof to probabilistic evidence by adapting study designs and value narratives to meet evolving expectations from regulators, HTA bodies, and payers
- Align early evidence generation with frameworks like the EU JCA to manage uncertainty, support reimbursement decisions, and accelerate patient access in an increasingly complex global landscape
Anirban Sadhu, VP, Global Regulatory Affairs, Teva Pharmaceuticals
- Transform HCP engagement quality by shifting from volume-driven outreach to evidence-based, persona-informed strategies grounded in real-world data
- Accelerate pre-launch readiness in the obesity market by mapping physician personas, patient profiles, and brand evolution, from 2023 to the competitive landscape today
Daniela Seixas, CEO, Tonic Easy Medical
- Identify root causes limiting digital health scalability – and realign expectations, resourcing, and governance to move beyond proof-of-concept
- Assess gaps in digital health capabilities, recognizing it demands distinct skills, operating models, and metrics from traditional pharma
Ashutosh Malhorta, Director Digital Health Strategy & Partnerships, Daiichi Sankyo
Moderator: Seth Ginsberg, Co-Founder & President, Global Healthy Living Foundation
- Identify priority evidence gaps by synthesising diverse data sources and competitive insights, and embed evidence-driven insights into asset development life cycles
- Achieve product differentiation by co-developing long-range, cross-functional evidence generation plans
Sayeh Tadayon, Global Director, Integrated Evidence Planning, Novo Nordisk
- Deploy AI cross-functionally to analyse behavioural, demographic, and engagement data that creates precise HCP personas based on preferences and decision-making to transform generic outreach into tailored experiences that increase response rates
- Accelerate personalised engagement by establishing feedback loops that track performance metrics and platform engagement across channels to continuously refine segmentation models and drive measurable improvements in reach and conversion
 Â
Marisa Muninger, Global Omnichannel Franchise Business Partner, Sanofi
Hugo Barbosa, EU Customer Omnichannel Director, ViiV Healthcare
Jens Øllgaard , Head of Customer Experience, Novo Nordisk Denmark
Ali Al-Bazergan, Global Head of Customer Experience Products, Commercial Innovation, Takeda
Ankit Sagar, Senior Vice President, Global Pharma, ON24
Yacin Marzouki, CEO, Biond Health
- Design unified, data platforms with embedded governance to ensure secure, interoperable, and AI-ready foundations for commercial and regulated environments
- Enable AI and analytics are simplified to scale by giving teams tested tools, templates, and reliable platforms ensuring successful pilots can quickly become repeatable solutions
Â
David Brown, Senior Director, Global Head of Data, Analytics & AI, ViiV HealthcareÂ
Mostafa Taha, VP, Head of Global Business Transformation, Merck
Gelsomino Centanni, Director Digital Data & IT, Novartis
Moderator: Alan Kalton, Principal, Axtria
Convert digital health data into commercial intelligence and improved patient outcomes through real-time insights
- Deploy digital health platforms that capture real-time patient adherence, symptom progression, and therapy response data to inform commercial forecasting, refine HCP targeting strategies, and optimise field force deployment for measurable revenue impact
- Transform continuous patient behavioural and outcomes data into actionable commercial insights that reduce costly HCP touchpoints, identify at-risk patients for early intervention, and validate pipeline investment decisions aligned with unmet market needs
Andrea Forgione, Global Head Access Policy, Patient Advocacy & Engagement, MENARINI Group
Jean van Wyk, Chief Medical Officer, ViiV Healthcare
Oana Butu, Global eHealth Lead, Abbott
Moderator: Francesca Chiara, Chair of the Board of Trustees, The AMR Narrative
- Strengthen reimbursement cases and inform long-term product strategy by integrating RWE earlier in development to address comparator data gaps, support trial design, and demonstrate real-world value across the product lifecycle
- Accelerate regulatory/payer decisions by designing comprehensive post-market data strategies that leverage AI-driven analysis to capture patient lifetime value at scale, particularly in areas with limited traditional evidence
Suzanne St Rose, Global RWE Head Eye Health & Emerging Areas, Pipeline Medical Affairs, Boehringer Ingelheim
Margaret Drysdale, Regional Head of Commercial Strategy, Plasma Derived Therapies, Takeda
Moderator: Ulka Campbell, SVP Scientific Strategy, Datavant
- Transform complex scientific insights into digestible formats to align with rapid consumption habits and expand reach amongst early-career prescribers who influence future treatment paradigms
- Drive meaningful engagement with next-gen HCPs by deploying platform-specific content strategies that leverage native video, trending formats, and peer-led storytelling to build brand awareness and credibility before traditional rep access is established
Alaa Alqraini, Senior Director, Digital & Customer Engagement Capabilities, IO-SO Medical and Marketing, Novo Nordisk
- Improve health outcomes through the systematic, standardised integration of patient reported outcome (PRO) assessments into routine clinical practice.
- Advance data driven decision making by enabling adaptive patient consent and implementing pragmatic core outcome sets (COS), supported by infrastructures that enable cross sector and pan European data aggregation—delivering actionable insights for research and policymaking.
Olga Alekseeva, Senior Director Global Digital Innovation, Global Digital Health, AstraZeneca
Meni Styliadou, VP, Health Data Partnerships, Data Science Institute, Takeda
- Achieve competitive positioning by identifying unmet needs and evidence gaps through strategic field-based insight generation from local market KOLs and health systems
- Maintain market success by translating these real-world insights into actionable cross-functional strategies that continually refine value positioning and differentiation throughout the product lifecycle
Ivo Hybrechts, Global Head Medical Insights, UCB
- How to achieve true content velocity and adaptability to make your content competitive and actually usable in the field
- How to make sales and marketing work together to achieve scalable personalization in content and experience
- How it works in practice: Leveraging Digital Opinion Leaders in your engagement strategy the right way
- Explaining the keystones behind better engagement in pharma
Nataliya Andreychuk, Co-Founder & CEO, Viseven
- Eliminate the data fragmentation and harmonisation gaps that prevent AI from generating credible clinical insights by deploying enterprise-grade, AI-ready storage architectures for genomic and multi-source datasets
- Strengthen regulatory compliance without sacrificing innovation speed by embedding governance frameworks and audit-ready data controls aligned to evolving EU requirements
Gary McAllister, CTO Healthcare & Public Sector, Dell Technologies
Hasan Jouni, EMEA Senior Partner Manager, Healthcare & Life Sciences, NVIDIA
- Discover how to future proof your organic strategy in an AI driven world where ChatGPT and AI overviews alter patient decision-making paths. Search journeys are already changed; traditional query volume is projected to drop 25% this year
- Learn how to engage patients effectively when AI becomes their first stop for answers and reshapes health information; 52% of consumers and 76% of HCPs already trust large language model outputs as accurate
Ben Myall, CEO, Everybody Agency
- Shift investment from declining web properties to direct channels like Instagram, TikTok, and LinkedIn to deliver bite-sized scientific content that reaches HCPs in real-time and drives measurable interaction
- Implement generative-AI-optimised content and track curated HCP journey metrics from discovery to conversion to demonstrate engagement impact beyond traditional web analytics
Â
Sihame Bahri, Global Omnichannel Lead, CSL
Dr Kishan Rees, Physician / Senior Director / Global Video Content & Digital Media Strategy- Patient & Scientific Engagement, Bayer
Dr Saima Sharif, Consultant Obstetrician & Gynaecologist, NHS Consultant
Moderator: Ed Hammerton, Head of Omnichannel Experience Design, Syneos Health
- Protect patients by defining where humans review automated insights and how explanations appear to business users
- Strengthen adoption by measuring accuracy, impact and updating review thresholds as confidence improves
Kris Bruynseels, VP, Global Head Integrated Insights, UCB
Gary McAllister, CTO Healthcare & Public Sector, Dell Technologies
Moderator: Saibal Mukherjee, Director, Global Data, Digital & Technology Legal, Takeda
- Create a continuous evidence chain linking engagement, PRO, and RWE data through a shared evidence governance council that sets quality thresholds and harmonises methodologies to translate narrative feedback into measurable endpoints validated through cross-functional analytics sprints
- Reinforce external credibility by publishing transparent ‘insight-to-impact' dashboards co-reviewed with payers, regulators, and patient representatives that demonstrate how evidence influences approval
Camille Lancelot, Community Manager, IFPA
Lisbeth Oxholm Snede, President, PiCC United
- Achieve optimal launch performance by establishing unified market intelligence and cross-functional governance between medical and commercial teams with shared insights on competitive dynamics, payer perspectives, and RWE
- Maximise market agility by syncing brand and value story via deploying field-based teams with real-time data sharing capabilities
Andrey Shutov, Launch Scientific Communications Director and Medical Hub Lead, Novartis
Denis Peeters, Global Head of Go-to-Market Capabilities (GTMC), Sanofi
Susana Gomez-Lus Centelles, President, AMIFE
Moderator: Gaetano Pellitteri, VP Field Medical Affairs Europe, Syneos Health
- Deploy digital pathways, wearables, and AI driven adherence platforms to enable direct, data powered patient engagement with measurable outcomes
- Accelerate therapy initiation and improve persistency by designing intelligent DTP ecosystems that balance access, trust, and adherence impact
- Generate actionable real world insights through direct patient engagement that informs evidence strategies and optimizes treatment delivery
Shayma Ali, VP, Patient Engagement & Support Services, IQVIA
Jara Soltero, Senior Director, Global Lead for Patient Offerings & Innovation, IQVIA
Nagore Fernandez-Dominguez, Director, Integrated Solutions, Patient Engagement & Support , IQVIA
- Walk through real omnichannel journey maps anchored at congress including the booth interaction, the symposium Q&A, the KOL side conversation and pinpoint exactly where the intelligence signal dies before it reaches your CRM, your rep, or your next campaign brief.
- Diagnose the gap together: Using live examples from your own commercial models, the group pressure-tests congress identity resolution, data flow, and field activation to surface what is actually lost between the congress floor and commercial action.
- Co-create the fix in the room: Leave with a peer-designed blueprint for turning congress into a live intelligence engine resolving HCP signals to CRM records, triggering field follow-up, and feeding omnichannel orchestration in real time.
*Please bring your laptop, this is a practical and interactive session
Pierre Metrailler, CEO, Onomi
- Gain insight into where AI tools for life sciences are heading, directly from those researching and building them
- Share learnings from AI implementations across pharma companies, with concrete examples from peers
- Co-develop a future-proof evaluation framework for AI tools to enable confident strategic decisions regarding new AI technology
Jungwon Byun, Co-founder, Elicit
Sheena Pulapaka, Lead, Strategic Accounts, Elicit
James Brady, Head of Engineering, Elicit
Harry Johnson, EMEA Commercial Lead, Elicit
- As IRA negotiations, MFN pricing dynamics, and EU Joint Clinical Assessment requirements continue to shift the access landscape, how should launch timelines be prepared to ensure optimal time to market?
- If your last launch were stress-tested against today's geopolitical and regulatory environment, what would fail first (the strategy stage, the evidence generation stage, or at the point of local affiliate execution?
Â
Pippa Postins, Global Head of Commercial Marketing, Global Pharma Strategy, Roche
Join a high-energy, hands-on AI Agents Hackathon and learn how to turn everyday tasks into autonomous workflows that work alongside your teams. Discover how commercial can elevate HCP engagement, medical can unlock actionable scientific insights, and clinical can accelerate site activation—while improving patient access and overall experience.
• Build your own: Collaborate to design an agent aligned to a real business challenge using a proven-and-tested approach.
• Leave with a blueprint: Walk away with a clear, scalable approach to launching and growing your agentic strategy.
Ihab Fakhouri, HLS GTM Lead, Salesforce
Zoe MacKinnon, Solution Leader, Patient Services, Salesforce
Venkat Swaminathan, Pharma Account Executive, Salesforce
Tom Smith, Vice President - Life Sciences, Salesforce
Anne Schaible, Regional VP Pharma & Healthcare, Salesforce
- Unlock faster market deployment and superior engagement by removing review bottlenecks through automated workflows that preserve quality standards
- Achieve unprecedented message alignment across regions by implementing intelligent consistency validation that enforces strategic coherence at scale
Â
Iria Gala, VP, Digital & Customer Engagement, Novo Nordisk
Sander Ruitenberg, Senior Director, Omnichannel Engagement, CSL
Yacin Marzouki, CEO, Biond Health
- Transform financial planning performance by replacing legacy processes with AI-driven workflows and building the change management infrastructure that makes adoption stick
- Accelerate enterprise AI ROI by applying the success factors and hard-won learnings from real-world finance transformation to your own deployment roadmap
Eduard Serrahima de Cambra, Director Data Science, Novartis
• Drive belief and build trust by crafting clear, compelling, and credible communications using novel technology that translate complex topics into meaningful narratives
• Master the art of data-driven dialogue, transforming complex evidence into clear, compelling insights that enable conversations and build conviction, giving HCPs the unwavering confidence to prescribe
Maggie Czarnogorski, Head, Digital Transformation & Strategic Innovation, ViiV Healthcare
- Accelerate forecast cycles and strengthen methodology consistency by embedding AI engines that generate multidimensional scenarios while transforming forecasters from model-builders to strategic curators
- Scale scenario exploration and decision-making velocity by operationalizing AI directly into commercial workflows that simulate thousands of outcomes autonomously
Tim Irfan, Commercial Programs Manager, Oracle Life Sciences, Oracle
Marina L. Martinez , Associate Principal, Digital and Data, Oracle
- Explore how digital health advisory boards bridge the gap between clinical needs and corporate innovation
- Discuss a peer-reviewed roadmap for overcoming barriers to help industry executives build more integrated, patient-centric healthcare ecosystems
Steven Januar Kusmanto, Global Director, Marketing & Digital Excellence, Menarini Group
- Align global and local teams through unified content workflows that enable rapid localisation and performance tracking to ensure affiliate-level execution drives measurable engagement outcomes
- Secure HCP preferred-partner status by embedding continuous feedback loops that capture real-world content performance and day-to-day information needs to inform future creation and demonstrate responsivenessÂ
Pippa Postins, Global Head of Commercial Marketing, Global Pharma Strategy, Roche
Carla Benedito, VP, Head of Global Commercial Operations, Takeda
Justin Schneller, Global Director, Content Excellence, CSL
Dr. Michael A. Kurr, Founder & Content Management Transformation Expert, Dr. Kurr AdvisoryÂ
Ravit Ansal , SVP, Chief Solutions Officer, Enterprise Commercial Solutions, Indegene
- Improve patient support by linking clinical, behavioural, and real-world data to form complete profiles, enabling tailored interventions and messaging that reflect actual patient needs.
- Transform connected data into predictive insights that inform strategic decisions, from patient adherence programs to HCP engagement tactics, driving measurable outcomes and long-term loyalty.
Â
Florent Hassen, Global Product Owner - AI & Omnichannel Advanced Analytics, Roche
Phoebos Stergiou, Head of Product Management, Omnichannel Customer Engagement, Digital Innovation, Senior Director, Gilead Sciences
Irena Brookes-Smith, Head of Healthcare Analytics, AstraZeneca
Sameer Singla, Principal, Data & AI, Axtria
Moderator: Jeppe Guilford Manuel, Director, Data Science EU External Affairs Partnerships, Novo Nordisk
- Co-design digital health with HCPs and patients, bake in privacy and consent lineage, and integrate into EHR workflows to earn trust, cut friction, and drive sustained clinical use
- Generate regulator- and HTA-grade evidence with clinical and economic endpoints, set reimbursement-ready contracts, and scale interoperable platforms to unlock access, data value, and measurable improvements in patient support and clinician care
Â
Loucif Ouyahia, Global Head of Digital Healthcare, Jazz Pharmaceuticals
Mitesh Daftardar, Head of Digital Innovation, Merz
Elcie Chan, EU Commercial Director – Digital Health, Otsuka
Moderator: Lisbeth Oxholm Snede, President, PiCC United
- Support successful market access by developing modular evidence packages: core clinical data for EU JCA, and tailored economic/contextual inputs for national HTAs
- Overcome local access barriers by creating bespoke solutions beyond harmonised clinical assessments
Batyrkhan Kuatov, Director HEOR, Global Market Access, CSL
Leyla Andrea Hernandez Donoso, Senior Director Real World Evidence, Data & Insights, Novo Nordisk
Laia Sole Feu, Global HTA, HEOR and Patient Advocacy Director, Almirall
- Uncovering the Blind Spot & Designing for Adoption: Understand the psychological root causes of why teams across commercial and medical workflows reject black-box AI models, and overcome this by co-creating fully traceable outputs with end-users, rather than just for them.
- Reducing Scepticism via Evidence-Based Implementation: Validate AI performance on real cases and establish behavioral impact metrics that commercial and medical teams can confidently challenge and trust.
Â
Jochen Baumeister, Head of Behavioral & Data Science / AI, Sandoz
• Vision to action: Advancing lived experience–led change and navigating today's policy opportunities and challenges
• Building the ecosystem: Practical insights and candid strategies to foster future-ready, meaningful patient partnerships across stakeholders
Vanessa Pott Semedo, Head of Patient Engagement, Boehringer Ingelheim
Valentina Strammiello, Interim Executive Director, EPF
- Establish market access as a core strategic function by building cross-functional bridges between pre-launch planning and post-launch execution, ensuring pricing strategies align with clinical and commercial objectives from day one
- Leverage increasing EU collaboration to navigate multi-country pricing and reimbursement pathways, sharing intelligence on reference pricing dynamics and coordinating submission strategies to optimise access timelines across markets
Keir Woods, VP, Global Value Demonstration, Market Access & Pricing (GVAP) - Oncology, Merck
Eirini Palaka, Business Unit Head Oncology, Ipsen
Moderator: Catarina Costa-Pinheiro, Head of Global Pricing, Ferrer
- What if your team could map the full patient journey, receive signals in real time, and tailor HCP engagement to each patient profile - all from continuous, qualitative data at scale?
- Learn how AI-driven patient interviews are giving commercial and medical teams a new kind of evidence base: Always-on, deeply qualitative, and publication-ready.
Mattia Marco Caruson, CEO and Founder, Mama Health
From customer obsession to knowledge obsession: How the next competitive edge will be built on what you already know
- Unlock enterprise AI value by transforming fragmented, siloed organisational knowledge into a structured, AI-operable intelligence asset that every function, from R&D to commercial, can access and act on
- Drive structural efficiency gains across Business Units by embedding a dynamic, living knowledge layer that powers smarter decision-making, informed by real-world cases from R&D insight to commercial execution
JoaquÃn Labado, Global Managing Director, Healthcare & Life Sciences, Globant
Javier Jimenez, Chief Medical Officer, PharmaMar
Design for life: Build connected patient experiences that drive confidence, continuity, and long-term engagement
- Understand how to integrate companion experiences into therapy pathways to maintain patient engagement between clinical touchpoints, whilst addressing emotional and practical challenges of living with chronic conditions
- Learn how AI can be applied ethically and effectively as an empathetic layer – enhancing patient understanding and personalisation without replacing human connection – to build trust and scalability in digital health ecosystems
Jesse Alvarez, Head of Consumer Experience, Sanofi
Moderator: Mark Duman, Patient Engagement Pioneer, MD Healthcare
- Create a smooth, end‑to‑end experience for customers by uniting medical, commercial, and support touchpoints and removing silos
- Build strategic advantage on a foundation of structured insights that convert customer data into clear, actionable decisions adapted to evolving generational needs
Â
Cyril Mandry, International Head of Omnichannel Customer Experience Oncology, MSD
Angela Genco, Transformational Marketing Head, Bayer Italy
Itziar Canamasas, Global Head of Oncology, Boehringer Ingelheim
Jana Sonntag, Head Customer Engagement Europe & Canada, AstraZeneca
Ben Finlay, Partner, Global Healthcare Advisory, Stratt
- Scale pilot projects by showcasing targeted use cases with clear inputs, safeguards, and explainability for business users
- Align vision and execution by standardising rollout kits (playbooks, success metrics) and assigning owners to scale across brands and geographies
Isabel Perez, Head Germany & Region Europe - Data & Digital IT, Novartis
Moderator: Jonathan Elliott, Director of Content Development, Thomson Reuters
- Map the patient engagement ecosystem to optimise channel selection with advocacy, digital opinion leaders, and direct-to-patient pathways against outcome metrics for insight, inclusion, and impact
- Define defensible investment criteria through outcome frameworks with establish enterprise standards that compare cost, credibility, and measurable system change across channels, making resource allocation transparent to leadership and regulators
Danuta Marchi, Global Head of Patient Engagement & Advocacy, UCB
Iria Gala, VP, Digital & Customer Engagement, Novo Nordisk
Lisbeth Oxholm Snede, President, PiCC United
Lena Förster, Principal, Temedica
Moderator: Mark Duman, Patient Engagement Pioneer, MD Healthcare
- Establish market access as a core strategic function by building cross-functional bridges between pre-launch planning and post-launch execution, ensuring pricing strategies align with clinical and commercial objectives from day one
- Leverage increasing EU collaboration to navigate multi-country pricing and reimbursement pathways, sharing intelligence on reference pricing dynamics and coordinating submission strategies to optimise access timelines across markets
Michela Pantaleoni, Chief Market Access Officer, Napo Therapeutics
Keir Woods, VP, Global Value Demonstration, Market Access & Pricing (GVAP) - Oncology, Merck
Eirini Palaka, Business Unit Head Oncology, Ipsen
Moderator: Catarina Costa-Pinheiro, Head of Global Pricing, Ferrer
- Reuters journalists take the audience inside their reporting on the growing pressures reshaping Europe’s pharmaceutical and global health landscape
- Drawing on coverage across European institutions, global health agencies, and Washington, the discussion examines how drugmakers are navigating tighter policy scrutiny in Europe alongside global health funding cuts following the U.S. withdrawal from the World Health Organization.
- Explore warnings of strain across multilateral institutions and the international spillover of U.S. vaccine politics, and what these developments signal for European and global health markets.
Â
This panel is hosted by Reuters journalists under the Reuters Trust Principles.
Â
Maggie Fick, European Pharmaceuticals Industry Correspondent, Reuters
Jennifer Rigby, Global Health Correspondent, Reuters
Moderator: Aislinn Laing, Iberia Co Bureau Chief, Reuters
Build the future together: Partner with health systems to deliver sustainable care and expand patient access
- Strengthen healthcare resilience by co-creating innovative solutions with health systems and technology partners that address system pressures, improve patient outcomes, and demonstrate measurable value
- Expand access and health equity by embedding shared strategic priorities across pharma, payers, providers, and communities through collaborative funding models and real-world evidence partnerships
Claire D'Abreu-Hayling, Chief Scientific Officer, Sandoz
António Charrua, General Manager Iberia, CSL
Dr Dana Vigier, VP, GM Alexion France & BeLux, Alexion
Moderator: Emma Sutcliffe, Founder & Chief Patient Officer, ISPEP
- Scientific innovation is accelerating — so why does it not reach patients reliably and in time? Exploring what's holding progress back and what it takes to remove those barriers.
- Rewire the way medicines are developed and delivered — by disease, by design, and across the health ecosystem — to turn structural change into smarter decisions, faster approvals, and accelerated impact for patients.
Lykke Hinsch Gylvin, Chief Medical Officer, Boehringer Ingelheim
Reuters Global Health Correspondent Jennifer Rigby sits down with Richard Horton, Editor in Chief of The Lancet, for an in depth conversation on the state of global health at a time of mounting political, economic, and scientific pressures. Horton will discuss the journal’s role in shaping global health debates, the challenges facing public health systems amid geopolitical instability, and how scientific institutions can maintain trust and independence in a polarized environment. The conversation will also explore emerging priorities in global health—from preparedness and pandemic governance to innovation, equity, and the future of medical research—offering rare insight from one of the field’s most influential editorial voices.
Richard Horton, Editor in Chief, The Lancet
Jennifer Rigby, Global Health Correspondent, Reuters
Â
This interview is conducted by a Reuters journalist under the Reuters Trust Principles
- Scale impact in low-resource settings by adopting inclusive business models, voluntary licensing frameworks, and collaborative partnerships with governments, NGOs, and global health organisations
- Strengthen long-term sustainability by aligning strategic innovations in access models with health system needs whilst leveraging generative AI and connected care data to reinforce
Agnese Cattaneo, Chief Medical Officer, Angelini Pharma
Roland Wandeler, President Biopharma, Grifols
Carolyn Paul, European Health Practice Chair, Edelman
Moderator: Jonathan Elliott, Director of Content Development, Thomson Reuters
- Strengthen Europe´s competitiveness in lifescience innovation and healthcare in light of geopolitical challenges – impact on operating models, access to medicines, and drug development
- Safeguard competitive positioning by embedding the patient voice into drug development and commercial strategy to prove value with pricing pressures
Carlos Gallardo, Chairman and Chief Executive Officer, Almirall and VP, EFPIA
Camille Lancelot, Community Manager, IFPA
- As pricing pressure shifts cost and risk toward patients, what does that mean for patient engagement—and for access itself? Explore how engagement becomes as critical as reimbursement in determining uptake and outcomes
- With European launches becoming harder to make the math work, can today's go-to-market models keep up? Examine whether traditional launch models can scale sustainably amid tighter budgets and rising complexity
- With innovation globalizing and geopolitics growing less stable, what role will Europe play in the decade ahead? Assess how China's emergence as a biopharma innovation powerhouse challenges assumptions about where innovation originates and scales
Bill Coyle, Managing Principal - Europe, ZS
- Strengthen global rare disease innovation momentum by building upon established regulatory frameworks and addressing evolving EU policy considerations that impact investment
- Accelerate early therapeutic intervention through AI-powered diagnostic tools that improve detection accuracy and reduce time to treatment
- Advance health equity by building multistakeholder collaboration models that unite payers, providers, and industry to expand patient access
Marc Dunoyer, Chief Executive Officer, Alexion
Reuters hosts a conversation with Cooke - who oversees the evaluation, authorisation and monitoring of medicines for more than 440 million people – about the factors shaping Europe’s pharmaceutical landscape at a critical moment for global health. In a live broadcast interview, Cooke will discuss how the EMA is handling rapid scientific innovation and the need to balance patient safety and public trust and industry needs. She’ll also look at what’s next for medicines regulation, including digital health, real-world evidence, manufacturing resilience and the increasingly complex geopolitics of global supply chains.
Â
Emer Cooke, Executive Director, The European Medicines Agency (EMA)
Maggie Fick, European Pharmaceuticals Industry Correspondent, Reuters
Â
This interview will be conducted under the Reuters Trust Principles
- Compound commercial performance over time by transforming CRM from a basic interface into an intelligence system that captures and leverages organisational memory as a strategic asset
- Drive context-aware engagement and automate commercial workflows at scale through AI agents that leverage collective data and intelligence
Stephen Wood, EMEA Regional Leader for Healthcare & Lifesciences, Microsoft
- Drive cross-functional excellence by dismantling silos through cross-functional insights and unified platforms that enable empowered teams to act faster
- Outpace competitors by strategically investing in AI tools at critical inflection points to automate workflows and accelerate time-to-market for innovation
Diana Medeiros Plácido, Chief Digital & Technology Officer, ViiV Healthcare
Chetak Buaria, VP, Global Commercial Operations, Merck
Tom Baker, SVP, Global Data, Technology, and Advisory Services, IQVIA
Question the foundations. Accelerate what matters. Shape a future of work that works for everyone.
- Drive sustainable transformation by establishing identity, confidence and psychological safety as core infrastructure for AI adoption
- Deliver representative outcomes by proactively dismantling bias in AI design and embedding inclusion as a strategic imperative
- Accelerate organisation-wide capability by cultivating leadership practices that inspire experimentation
Dagmar Albers, VP EMEA, Healthcare Businesswomen's Association
Sarah Dancy Blackburn, Director of Value EMEA, Healthcare Businesswomen's Association
- Reuters journalists take the audience inside their reporting on the growing pressures reshaping Europe’s pharmaceutical and global health landscape
- Drawing on coverage across European institutions, global health agencies, and Washington, the discussion examines how drugmakers are navigating tighter policy scrutiny in Europe alongside global health funding cuts following the U.S. withdrawal from the World Health Organization.
- Explore warnings of strain across multilateral institutions and the international spillover of U.S. vaccine politics, and what these developments signal for European and global health markets.
Â
This panel is hosted by Reuters journalists under the Reuters Trust Principles.
Â
Maggie Fick, European Pharmaceuticals Industry Correspondent, Reuters
Jennifer Rigby, Global Health Correspondent, Reuters
Moderator: Aislinn Laing, Iberia Co Bureau Chief, Reuters
Build the future together: Partner with health systems to deliver sustainable care and expand patient access
- Strengthen healthcare resilience by co-creating innovative solutions with health systems and technology partners that address system pressures, improve patient outcomes, and demonstrate measurable value
- Expand access and health equity by embedding shared strategic priorities across pharma, payers, providers, and communities through collaborative funding models and real-world evidence partnerships
Â
Claire D'Abreu-Hayling, Chief Scientific Officer, Sandoz
António Charrua, General Manager Iberia, CSL
Dr Dana Vigier, VP, GM Alexion France & BeLux, Alexion
Moderator: Emma Sutcliffe, Founder & Chief Patient Officer, ISPEP
- Scientific innovation is accelerating — so why does it not reach patients reliably and in time? Exploring what's holding progress back and what it takes to remove those barriers.
- Rewire the way medicines are developed and delivered — by disease, by design, and across the health ecosystem — to turn structural change into smarter decisions, faster approvals, and accelerated impact for patients.
Lykke Hinsch Gylvin, Chief Medical Officer, Boehringer Ingelheim
Reuters Global Health Correspondent Jennifer Rigby sits down with Richard Horton, Editor in Chief of The Lancet, for an in depth conversation on the state of global health at a time of mounting political, economic, and scientific pressures. Horton will discuss the journal’s role in shaping global health debates, the challenges facing public health systems amid geopolitical instability, and how scientific institutions can maintain trust and independence in a polarized environment. The conversation will also explore emerging priorities in global health—from preparedness and pandemic governance to innovation, equity, and the future of medical research—offering rare insight from one of the field’s most influential editorial voices.
Richard Horton, Editor in Chief, The Lancet
Jennifer Rigby, Global Health Correspondent, Reuters
This interview is conducted by a Reuters journalist under the Reuters Trust Principles
- Scale impact in low-resource settings by adopting inclusive business models, voluntary licensing frameworks, and collaborative partnerships with governments, NGOs, and global health organisations
- Strengthen long-term sustainability by aligning strategic innovations in access models with health system needs whilst leveraging generative AI and connected care data to reinforce
Â
Agnese Cattaneo, Chief Medical Officer, Angelini Pharma
Roland Wandeler, President Biopharma, Grifols
Carolyn Paul, European Health Practice Chair, Edelman
Moderator: Jonathan Elliott, Director of Content Development, Thomson Reuters
- Elevate your position as an HCP partner by deploying AI-powered digital platforms that facilitate more effective communication between HCPs and their patients
- Improve patient health outcomes and access to care by embedding personalised, user-friendly tools that connect patients to critical treatment information at the point of need
Philippe Pinton, SVP, Head, Global Research and Medical, Ferring Pharmaceuticals
Dr Dana Vigier, VP, GM Alexion France & BeLux, Alexion
Jean‑Philippe Plançon, Chairman of the Board and President, EPODIN (European Patients Organization for Dysimune & Inflammatory Neuropathies)
Sabine Louët, Founder & Chief Executive Officer, SciencePOD
- Simulate impact before deployment to de-risk channel mix, refine access pathways, and prioritise high-yield HCP engagement
- Align global strategy with local execution through modular playbooks, clear governance, and co-ordinated field–digital actions
- Optimise territories, incentives, and resource allocation in-cycle using real-time signals and next-best-action engines
Fleur Gill, VP Sales & Partnerships - Global, Doceree
- Accelerate innovation cycles and deliver ecosystem-wide value by embedding patient insights and visualising the journey from clinical trials to market
- Amplify patient outcomes by creating bidirectional HCP-patient communication channels that transform medical communications into insight-rich exchanges
Maria Galindo Perez, VP, Global Head of Publications, Bayer
Isabelle Lonjon-Domanec, VP, Clinical Medical Regulatory, Novo Nordisk
Samantha Scheer, Head of Global Medical Communications, Neurology & Immunology, Merck
Sarah Frazer, VP, Head of Medical Strategy, Real Chemistry
- Build AI literacy through structured capability programs that teach reps to interpret predictive HCP signals and prioritise outreach to increase meeting acceptance rates and message receptivity
- Embed next-best-action recommendations directly into CRM and mobile tools to deliver timely, personalised content for every HCP interaction that accelerates prescribing behaviour
Arun Nair, Head of International Commercial - Data & Analytics (IT), Gilead
- Accelerate strategic decision-making by leveraging exclusive 2026 research findings on field excellence priorities, critical trade-offs and emerging themes
- Drive cross-functional transformation across Sales, Marketing, Medical and Market Access by converting research insights into actionable field excellence strategies tailored to your business objectives
Â
Steph Plowright, Director of Strategy & Innovation, Nazaré, part of Inizio Engage
Wil Procter, Director of Strategy & Innovation, Nazaré, part of Inizio Engage
- Equip field teams to translate real-time HCP signals such as channel-preference shifts and content engagement patterns into prioritised actions that increase meeting conversion rates and accelerate prescribing decisions
- Align upskilling programmes to commercial KPIs that validate field effectiveness, including HCP engagement depth, message recall, and territory-level script growth to demonstrate measurable ROI
Chetak Buaria, VP, Global Commercial Operations, Merck
Philippe Guisset, Business Unit Director, Alfasigma
Dr. Konstanze Wagner, Executive Director Strategy & Operations, Bristol Myers Squibb Germany
Michael Zaiac, Head of Medical Affairs Oncology EUCAN, Daiichi Sankyo
Moderator: Sam Rolfe, Sales Director, Exeevo
Session Description
- Identify the optimal moments and channels to engage HCPs by mapping the customer journey against strategic business objectives, driving seamless engagement across relevant platforms for your organisation
- Foster meaningful connections with HCPs through intelligent orchestration that personalises interactions and responds to individual needs, building rapport and trust
Sander Ruitenberg, Senior Director, Omnichannel Engagement, CSLÂ
- Deploy AI cross-functionally to analyse behavioural, demographic, and engagement data that creates precise HCP personas based on preferences and decision-making to transform generic outreach into tailored experiences that increase response rates
- Accelerate personalised engagement by establishing feedback loops that track performance metrics and platform engagement across channels to continuously refine segmentation models and drive measurable improvements in reach and conversion
 Â
Marisa Muninger, Global Omnichannel Franchise Business Partner, Sanofi
Hugo Barbosa, EU Customer Omnichannel Director, ViiV Healthcare
Jens Øllgaard , Head of Customer Experience, Novo Nordisk Denmark
Ali Al-Bazergan, Global Head of Customer Experience Products, Commercial Innovation, Takeda
Ankit Sagar, Senior Vice President, Global Pharma, ON24
Yacin Marzouki, CEO, Biond Health
- Transform complex scientific insights into digestible formats to align with rapid consumption habits and expand reach amongst early-career prescribers who influence future treatment paradigms
- Drive meaningful engagement with next-gen HCPs by deploying platform-specific content strategies that leverage native video, trending formats, and peer-led storytelling to build brand awareness and credibility before traditional rep access is established
Â
Alaa Alqraini, Senior Director, Digital & Customer Engagement Capabilities, IO-SO Medical and Marketing, Novo Nordisk
- How to achieve true content velocity and adaptability to make your content competitive and actually usable in the field
- How to make sales and marketing work together to achieve scalable personalization in content and experience
- How it works in practice: Leveraging Digital Opinion Leaders in your engagement strategy the right way
- Explaining the keystones behind better engagement in pharma
Nataliya Andreychuk, Co-Founder & CEO, Viseven
- Shift investment from declining web properties to direct channels like Instagram, TikTok, and LinkedIn to deliver bite-sized scientific content that reaches HCPs in real-time and drives measurable interaction
- Implement generative-AI-optimised content and track curated HCP journey metrics from discovery to conversion to demonstrate engagement impact beyond traditional web analytics
Â
Sihame Bahri, Global Omnichannel Lead, CSL
Dr Kishan Rees, Physician / Senior Director / Global Video Content & Digital Media Strategy- Patient & Scientific Engagement, Bayer
Dr Saima Sharif, Consultant Obstetrician & Gynaecologist, NHS Consultant
Moderator: Ed Hammerton, Head of Omnichannel Experience Design, Syneos Health
- Unlock faster market deployment and superior engagement by removing review bottlenecks through automated workflows that preserve quality standards
- Achieve unprecedented message alignment across regions by implementing intelligent consistency validation that enforces strategic coherence at scale
Â
Iria Gala, VP, Digital & Customer Engagement, Novo Nordisk
Sander Ruitenberg, Senior Director, Omnichannel Engagement, CSL
Yacin Marzouki, CEO, Biond Health
- Align global and local teams through unified content workflows that enable rapid localisation and performance tracking to ensure affiliate-level execution drives measurable engagement outcomes
- Secure HCP preferred-partner status by embedding continuous feedback loops that capture real-world content performance and day-to-day information needs to inform future creation and demonstrate responsivenessÂ
Pippa Postins, Global Head of Commercial Marketing, Global Pharma Strategy, Roche
Carla Benedito, VP, Head of Global Commercial Operations, Takeda
Justin Schneller, Global Director, Content Excellence, CSL
Dr. Michael A. Kurr, Founder & Content Management Transformation Expert, Dr. Kurr AdvisoryÂ
Ravit Ansal , SVP, Chief Solutions Officer, Enterprise Commercial Solutions, Indegene
- What if your team could map the full patient journey, receive signals in real time, and tailor HCP engagement to each patient profile - all from continuous, qualitative data at scale?
- Learn how AI-driven patient interviews are giving commercial and medical teams a new kind of evidence base: Always-on, deeply qualitative, and publication-ready.
Â
Mattia Marco Caruson, CEO and Founder, Mama Health
- Create a smooth, end‑to‑end experience for customers by uniting medical, commercial, and support touchpoints and removing silos
- Build strategic advantage on a foundation of structured insights that convert customer data into clear, actionable decisions adapted to evolving generational needs
Â
Cyril Mandry, International Head of Omnichannel Customer Experience Oncology, MSD
Angela Genco, Transformational Marketing Head, Bayer Italy
Itziar Canamasas, Global Head of Oncology, Boehringer Ingelheim
Jana Sonntag, Head Customer Engagement Europe & Canada, AstraZeneca
Ben Finlay, Partner, Global Healthcare Advisory, Stratt
- Transform fragmented data into accessible, high-quality strategic assets by implementing FAIR principles that ensure quality and scale across the enterprise
- Accelerate breakthrough outcomes from in silico research to supply chain optimization through secure-by-design platforms that enable confident adoption of autonomous agentic workflows
Â
Ralf Schundelmeier, Head of Enterprise Data and Platforms, Boehringer Ingelheim
- Transform disconnected AI pilots into a governed, enterprise-wide operating model by deploying agentic orchestration across R&D, clinical development, and commercial operations
- Drive compounding enterprise value by executing a practical roadmap that converts isolated use cases into end-to-end agentic workflows with measurable, board-ready ROI
Johanna DeYoung, Global Industry Lead, Healthcare & Life Sciences, Slalom
- Sustain trust at scale by proving stewardship and reviewing transparency metrics with advisory input each quarter
- Enable collaborative data ecosystems by investing in shared registries and quality standards, creating the foundation for outcome-based pricing and innovative reimbursement models
Â
Meni Styliadou, VP Global Program Leader – Health Data Partnerships, Takeda
Moderator: Charlotte Brimacombe, Head of Pharma, Reuters Events
- Improve journey consistency by unifying profiles and hierarchies – such as customer matching and product lists – across commercial, medical, and access teams
- Raise relevance by governing stewardship and quality with business ownership and a shared data catalog
Shreenivasa Rajanala, Global Head of Data Analytics and AI Foundations, Global Commercialisation, Bayer
- Drive measurable field force effectiveness by closing the gap between CRM data generation and HCP-facing execution through harmonised, real-time data pipelines
- Embed next-best-action intelligence directly into field workflows to accelerate commercial decision-making at the point of engagement
Jonathan Vitale, Business Development Lead, Trueblue
Hartmann Estruch, Commercial Excellence & Customer Centricity Iberia Director, Zambon S.A.U.
- Accelerate initiatives by defining data owners, access paths, decision rights and approval workflows for priority customer data sets
- Build confidence by tracking policy adherence and resolving issues in monthly cross‑functional data councils to daily commercial activities
- Transform customer data into compelling narratives that engage audiences emotionally while delivering quantifiable business results
Chris Duarte, Head of Data, Analytics and Insight, ViiV Healthcare
Moderator: Marta Diaz, Head of Data Strategy, Platform and Governance, Novartis
- Architect and scale unified, governed data platforms that enable secure, interoperable, and AI-ready foundations for R&D, diagnostics, and commercial use cases
- Accelerate analytics and AI adoption through self-service enablement and platform-as-a-product capabilities, ensuring teams deliver insights faster while maintaining compliance and cost efficiency
Â
Kishan Rees, Senior Director Video & Media Content Strategy, Bayer
Tom Keith-Welsh, Client Partner, Bayer
- Transform HCP engagement quality by shifting from volume-driven outreach to evidence-based, persona-informed strategies grounded in real-world data
- Accelerate pre-launch readiness in the obesity market by mapping physician personas, patient profiles, and brand evolution, from 2023 to the competitive landscape today
Â
Daniela Seixas, CEO, Tonic Easy Medical
- Design unified, data platforms with embedded governance to ensure secure, interoperable, and AI-ready foundations for commercial and regulated environments
- Enable AI and analytics are simplified to scale by giving teams tested tools, templates, and reliable platforms ensuring successful pilots can quickly become repeatable solutions
David Brown, Senior Director, Global Head of Data, Analytics & AI, ViiV HealthcareÂ
Mostafa Taha, VP, Head of Global Business Transformation, Merck
Gelsomino Centanni, Director Digital Data & IT, Novartis
Moderator: Alan Kalton, Principal, Axtria
- Eliminate the data fragmentation and harmonisation gaps that prevent AI from generating credible clinical insights by deploying enterprise-grade, AI-ready storage architectures for genomic and multi-source datasets
- Strengthen regulatory compliance without sacrificing innovation speed by embedding governance frameworks and audit-ready data controls aligned to evolving EU requirements
Â
Gary McAllister, CTO Healthcare & Public Sector, Dell Technologies
Hasan Jouni, EMEA Senior Partner Manager, Healthcare & Life Sciences, NVIDIA
- Protect patients by defining where humans review automated insights and how explanations appear to business users
- Strengthen adoption by measuring accuracy, impact and updating review thresholds as confidence improves
Kris Bruynseels, VP, Global Head Integrated Insights, UCB
Gary McAllister, CTO Healthcare & Public Sector, Dell Technologies
Moderator: Saibal Mukherjee, Director, Global Data, Digital & Technology Legal, Takeda
- Transform financial planning performance by replacing legacy processes with AI-driven workflows and building the change management infrastructure that makes adoption stick
- Accelerate enterprise AI ROI by applying the success factors and hard-won learnings from real-world finance transformation to your own deployment roadmap
Â
Eduard Serrahima de Cambra, Director Data Science, Novartis
- Accelerate forecast cycles and strengthen methodology consistency by embedding AI engines that generate multidimensional scenarios while transforming forecasters from model-builders to strategic curators
- Scale scenario exploration and decision-making velocity by operationalizing AI directly into commercial workflows that simulate thousands of outcomes autonomously
Tim Irfan, Commercial Programs Manager, Oracle Life Sciences, Oracle
Marina L. Martinez , Associate Principal, Digital and Data, Oracle
- Improve patient support by linking clinical, behavioural, and real-world data to form complete profiles, enabling tailored interventions and messaging that reflect actual patient needs.
- Transform connected data into predictive insights that inform strategic decisions, from patient adherence programs to HCP engagement tactics, driving measurable outcomes and long-term loyalty.
Florent Hassen, Global Product Owner - AI & Omnichannel Advanced Analytics, Roche
Phoebos Stergiou, Head of Product Management, Omnichannel Customer Engagement, Digital Innovation, Senior Director, Gilead Sciences
Irena Brookes-Smith, Head of Healthcare Analytics, AstraZeneca
Sameer Singla, Principal, Data & AI, Axtria
Moderator: Jeppe Guilford Manuel, Director, Data Science EU External Affairs Partnerships, Novo Nordisk
- Uncovering the Blind Spot & Designing for Adoption: Understand the psychological root causes of why teams across commercial and medical workflows reject black-box AI models, and overcome this by co-creating fully traceable outputs with end-users, rather than just for them.
- Reducing Scepticism via Evidence-Based Implementation: Validate AI performance on real cases and establish behavioral impact metrics that commercial and medical teams can confidently challenge and trust.
Jochen Baumeister, Head of Behavioral & Data Science / AI, Sandoz
From customer obsession to knowledge obsession: How the next competitive edge will be built on what you already know
- Unlock enterprise AI value by transforming fragmented, siloed organisational knowledge into a structured, AI-operable intelligence asset that every function, from R&D to commercial, can access and act on
- Drive structural efficiency gains across Business Units by embedding a dynamic, living knowledge layer that powers smarter decision-making, informed by real-world cases from R&D insight to commercial execution
JoaquÃn Labado, Global Managing Director, Healthcare & Life Sciences, Globant
Javier Jimenez, Chief Medical Officer, PharmaMar
- Scale pilot projects by showcasing targeted use cases with clear inputs, safeguards, and explainability for business users
- Align vision and execution by standardising rollout kits (playbooks, success metrics) and assigning owners to scale across brands and geographies
Â
Isabel Perez, Head Germany & Region Europe - Data & Digital IT, Novartis
Moderator: Jonathan Elliott, Director of Content Development, Thomson Reuters
- Co-creation with patients is reshaping the way pharma companies define and design the ideal patient experience – move from assumption-led models to ones built on real-world needs and lived experience
- Ground the future of patient experience in the real world: explore specific disease area use cases where innovative design is making a measurable difference
Karima Siddiqui, Global Director Patient Health Excellence, Takeda
Daniel Leutenegger, Global Director Patient Health Excellence, Takeda
- Deliver intelligent, agent-orchestrated PSPs to transform traditional support into autonomous, always-on care systems that proactively coordinate onboarding, drive adherence and respond to evolving patient needs in real time.
- Measure what matters by using real time data and connected analytics to link awareness, adherence, persistence, and patient experience, shifting focus from task volume to meaningful patient and business outcomes
Ihab Fakhouri, HLS GTM Lead, Salesforce
- Embed tested strategies for winning internal stakeholder support by presenting PSP business cases that connect patient-centric program design to measurable commercial outcomes and long-term brand differentiation
- Evaluate what successful PSPs actually deliver in practice through multi-stakeholder perspectives to create your actionable optimisation roadmap that balances patient needs, operational agility, and strategic business objectives
Â
Sarah Mertens, Head of UCBCares & Patient Support Global, UCB
Ana Maria, Global Director, Patient Experience, Pfizer
Geoff Rollason, Patient/Patient Advocate
Moderator: Seth Ginsberg, Co-Founder & President, Global Healthy Living Foundation
- Generate continuous patient outcome and behavioural insights from digital health tools and platforms that strengthen HCP capabilities
- Enhance HCP engagement through digital health outputs that address real world information gaps with patient behavior analytics
Richard Cassidy, SVP and President of the Rx+ Business Accelerator, Astellas
• Move beyond pilots: how pharma, hospitals and startups can co-create digital solutions that improve patient follow-up
• Turn innovation into adoption: lessons learned in transferring innovation into real clinical pathways
Omar Al-Nehlawi Valverde, Head of Innovation & Patient Centric Solutions, Amgen
- Implement patient data education frameworks that directly increase consent rates and data-sharing participation to unlock high-quality RWE for decision-makers and product differentiation
- Quantify the ROI of digital health initiatives by tracking conversion metrics from education touchpoints to digital health enrolment and improved medication adherence, thereby enhancing patient lifetime value across portfolios
Â
Grégoire Guillet, Chief Business & Value Officer - Digital Factory, Servier
Johannes Munding, Director Patient Experience, Novartis
Patricia Ripoll, Founder & President, Fundación
David Braun, Head of Commercial Operations and Customer Engagement Global Digital Health, Merck
Moderator: Seth Ginsberg, Co-Founder & President, Global Healthy Living Foundation
- Recruit and partner with KOLs, HCPs and patient organisations to raise digital health confidence and value
- Revolutionise HCP perception and scale compliant promotion by strategically positioning influential digital health leaders as product champions
Â
Emre Ozcan, SVP Global Head of Digital Health & Devices, Merck
Moderator: Seth Ginsberg, Co-Founder & President, Global Healthy Living Foundation
- Identify root causes limiting digital health scalability – and realign expectations, resourcing, and governance to move beyond proof-of-concept
- Assess gaps in digital health capabilities, recognizing it demands distinct skills, operating models, and metrics from traditional pharma
Â
Ashutosh Malhorta, Director Digital Health Strategy & Partnerships, Daiichi Sankyo
Moderator: Seth Ginsberg, Co-Founder & President, Global Healthy Living Foundation
Convert digital health data into commercial intelligence and improved patient outcomes through real-time insights
- Deploy digital health platforms that capture real-time patient adherence, symptom progression, and therapy response data to inform commercial forecasting, refine HCP targeting strategies, and optimise field force deployment for measurable revenue impact
- Transform continuous patient behavioural and outcomes data into actionable commercial insights that reduce costly HCP touchpoints, identify at-risk patients for early intervention, and validate pipeline investment decisions aligned with unmet market needs
Â
Andrea Forgione, Global Head Access Policy, Patient Advocacy & Engagement, MENARINI Group
Jean van Wyk, Chief Medical Officer, ViiV Healthcare
Oana Butu, Global eHealth Lead, Abbott
Moderator: Francesca Chiara, Chair of the Board of Trustees, The AMR Narrative
- Improve health outcomes through the systematic, standardised integration of patient reported outcome (PRO) assessments into routine clinical practice.
- Advance data driven decision making by enabling adaptive patient consent and implementing pragmatic core outcome sets (COS), supported by infrastructures that enable cross sector and pan European data aggregation—delivering actionable insights for research and policymaking.
Olga Alekseeva, Senior Director Global Digital Innovation, Global Digital Health, AstraZeneca
Meni Styliadou, VP, Health Data Partnerships, Data Science Institute, Takeda
- Discover how to future proof your organic strategy in an AI driven world where ChatGPT and AI overviews alter patient decision-making paths. Search journeys are already changed; traditional query volume is projected to drop 25% this year
- Learn how to engage patients effectively when AI becomes their first stop for answers and reshapes health information; 52% of consumers and 76% of HCPs already trust large language model outputs as accurate
Ben Myall, CEO, Everybody Agency
- Create a continuous evidence chain linking engagement, PRO, and RWE data through a shared evidence governance council that sets quality thresholds and harmonises methodologies to translate narrative feedback into measurable endpoints validated through cross-functional analytics sprints
- Reinforce external credibility by publishing transparent ‘insight-to-impact' dashboards co-reviewed with payers, regulators, and patient representatives that demonstrate how evidence influences approval
Camille Lancelot, Community Manager, IFPA
Lisbeth Oxholm Snede, President, PiCC United
• Drive belief and build trust by crafting clear, compelling, and credible communications using novel technology that translate complex topics into meaningful narratives
• Master the art of data-driven dialogue, transforming complex evidence into clear, compelling insights that enable conversations and build conviction, giving HCPs the unwavering confidence to prescribe
Maggie Czarnogorski, Head, Digital Transformation & Strategic Innovation, ViiV Healthcare
- Explore how digital health advisory boards bridge the gap between clinical needs and corporate innovation
- Discuss a peer-reviewed roadmap for overcoming barriers to help industry executives build more integrated, patient-centric healthcare ecosystems
Â
Steven Januar Kusmanto, Global Director, Marketing & Digital Excellence, Menarini Group
- Co-design digital health with HCPs and patients, bake in privacy and consent lineage, and integrate into EHR workflows to earn trust, cut friction, and drive sustained clinical use
- Generate regulator- and HTA-grade evidence with clinical and economic endpoints, set reimbursement-ready contracts, and scale interoperable platforms to unlock access, data value, and measurable improvements in patient support and clinician care
Loucif Ouyahia, Global Head of Digital Healthcare, Jazz Pharmaceuticals
Mitesh Daftardar, Head of Digital Innovation, Merz
Elcie Chan, EU Commercial Director – Digital Health, Otsuka
Moderator: Lisbeth Oxholm Snede, President, PiCC United
• Vision to action: Advancing lived experience–led change and navigating today's policy opportunities and challenges
• Building the ecosystem: Practical insights and candid strategies to foster future-ready, meaningful patient partnerships across stakeholders
Vanessa Pott Semedo, Head of Patient Engagement, Boehringer Ingelheim
Valentina Strammiello, Interim Executive Director, EPF
Design for life: Build connected patient experiences that drive confidence, continuity, and long-term engagement
- Understand how to integrate companion experiences into therapy pathways to maintain patient engagement between clinical touchpoints, whilst addressing emotional and practical challenges of living with chronic conditions
- Learn how AI can be applied ethically and effectively as an empathetic layer – enhancing patient understanding and personalisation without replacing human connection – to build trust and scalability in digital health ecosystems
Jesse Alvarez, Head of Consumer Experience, Sanofi
Moderator: Mark Duman, Patient Engagement Pioneer, MD Healthcare
- Map the patient engagement ecosystem to optimise channel selection with advocacy, digital opinion leaders, and direct-to-patient pathways against outcome metrics for insight, inclusion, and impact
- Define defensible investment criteria through outcome frameworks with establish enterprise standards that compare cost, credibility, and measurable system change across channels, making resource allocation transparent to leadership and regulators
Â
Danuta Marchi, Global Head of Patient Engagement & Advocacy, UCB
Iria Gala, VP, Digital & Customer Engagement, Novo Nordisk
Lisbeth Oxholm Snede, President, PiCC United
Lena Förster, Principal, Temedica
Moderator: Mark Duman, Patient Engagement Pioneer, MD Healthcare
- Unlock a proven reform framework that reduces patient cost burden by 40–65% without manufacturer price cuts — redirecting market access strategy toward distribution and tax structures
- Immediate reform opportunities from 35-country research by identifying where distribution margin and VAT reform create the fastest, most durable affordability and patient access gains
Giovanny Leon, Chair, Medicines Affordability & Adherence Alliance
- Accelerate critical decision-making at key value inflection points by anticipating IRA, JCA, and MFN policy impacts on development pathways
- Transform commercialisation models and build integrated evidence strategies that demonstrate value across evolving healthcare systems through cross-functional capabilities
Steve Mather, Joint Global Practice Lead, Strategy & Insight, Lumanity
- Drive pre-launch readiness by engaging with medical societies, government health agencies, and clinical communities to improve diagnostic rates, shape policy, and address unmet needs ahead of launch
- Optimise uptake during launch by deploying field-based teams to identify reimbursement barriers and co-create solutions with health authorities, insurers, and hospital systems at regional levels
Â
Clara Rodriguez, Director, Market Access Oncology, Pfizer
Kemal Uca, VP, Head of Global Market Access & Pricing Cardiovascular Metabolism & Endocrinology and Fertility, Merck
Karen Lightning-Jones, Pricing, Reimbursement, Policy and Communications Lead, Roche
Moderator: Jonathan Elliott, Director of Content Development, Thomson Reuters
- Accelerate evidence-based launch decisions by integrating AI capabilities that validate differentiation and stress-test value assumptions before market entry
- Strengthen global pricing defensibility by bridging development and commercialisation with MFN-ready access strategies and evidence generation
Daniel Zolnierz, VP New Product Planning, Neurology & Immunology, Merck
Keir Woods, VP, Global Value Demonstration, Market Access & Pricing (GVAP) - Oncology, Merck
- Plan smarter and align faster with AI to achieve launch precision and effectiveness
- Execute intelligently to drive day-one impact and sustained value
Â
Sarah Rickwood, VP, Thought Leadership, IQVIA
Natalie Harb, VP, Offering Development – Launch Excellence, IQVIA
Peter Thomsen, Global Assoc. Launch Director, Obesity, Novo Nordisk
- Maximise global revenue via building adaptive launch frameworks that respond to market complexity
- Optimise product value realisation across diverse markets by exploring strategic sequencing approaches and leverage analytics to inform long-term commercial decisions
Â
Michele Siccardi, Executive Director, Head of International (ex US) Insights & Analytics, CSL
Ulf Staginnus, VP International Market Access & Pricing, Blueprint Medicines (A Sanofi Company)
Silvia Maeso, VP, Global Market Access, Health Economics, Pricing and HTA, Almirall
Moderator: Gerardo Martinez, Senior Director, Global Market Access - Pipeline (Immunology & Rare Disease), CSL
- Navigate the shift from absolute proof to probabilistic evidence by adapting study designs and value narratives to meet evolving expectations from regulators, HTA bodies, and payers
- Align early evidence generation with frameworks like the EU JCA to manage uncertainty, support reimbursement decisions, and accelerate patient access in an increasingly complex global landscape
Anirban Sadhu, VP, Global Regulatory Affairs, Teva Pharmaceuticals
- Identify priority evidence gaps by synthesising diverse data sources and competitive insights, and embed evidence-driven insights into asset development life cycles
- Achieve product differentiation by co-developing long-range, cross-functional evidence generation plans
Â
Sayeh Tadayon, Global Director, Integrated Evidence Planning, Novo Nordisk
- Strengthen reimbursement cases and inform long-term product strategy by integrating RWE earlier in development to address comparator data gaps, support trial design, and demonstrate real-world value across the product lifecycle
- Accelerate regulatory/payer decisions by designing comprehensive post-market data strategies that leverage AI-driven analysis to capture patient lifetime value at scale, particularly in areas with limited traditional evidence
Â
Suzanne St Rose, Global RWE Head Eye Health & Emerging Areas, Pipeline Medical Affairs, Boehringer Ingelheim
Margaret Drysdale, Regional Head of Commercial Strategy, Plasma Derived Therapies, Takeda
Moderator: Ulka Campbell, SVP Scientific Strategy, Datavant
- Achieve competitive positioning by identifying unmet needs and evidence gaps through strategic field-based insight generation from local market KOLs and health systems
- Maintain market success by translating these real-world insights into actionable cross-functional strategies that continually refine value positioning and differentiation throughout the product lifecycle
Ivo Hybrechts, Global Head Medical Insights, UCB
- Achieve optimal launch performance by establishing unified market intelligence and cross-functional governance between medical and commercial teams with shared insights on competitive dynamics, payer perspectives, and RWE
- Maximise market agility by syncing brand and value story via deploying field-based teams with real-time data sharing capabilities
Â
Andrey Shutov, Launch Scientific Communications Director and Medical Hub Lead, Novartis
Denis Peeters, Global Head of Go-to-Market Capabilities (GTMC), Sanofi
Susana Gomez-Lus Centelles, President, AMIFE
Moderator: Gaetano Pellitteri, VP Field Medical Affairs Europe, Syneos Health
- Support successful market access by developing modular evidence packages: core clinical data for EU JCA, and tailored economic/contextual inputs for national HTAs
- Overcome local access barriers by creating bespoke solutions beyond harmonised clinical assessments
Â
Batyrkhan Kuatov, Director HEOR, Global Market Access, CSL
Leyla Andrea Hernandez Donoso, Senior Director Real World Evidence, Data & Insights, Novo Nordisk
Laia Sole Feu, Global HTA, HEOR and Patient Advocacy Director, Almirall
- Establish market access as a core strategic function by building cross-functional bridges between pre-launch planning and post-launch execution, ensuring pricing strategies align with clinical and commercial objectives from day one
- Leverage increasing EU collaboration to navigate multi-country pricing and reimbursement pathways, sharing intelligence on reference pricing dynamics and coordinating submission strategies to optimise access timelines across markets
Keir Woods, VP, Global Value Demonstration, Market Access & Pricing (GVAP) - Oncology, Merck
Eirini Palaka, Business Unit Head Oncology, Ipsen
Moderator: Catarina Costa-Pinheiro, Head of Global Pricing, Ferrer
- Strengthen reimbursement outcomes by integrating payer evidence requirements such as cost‑effectiveness, quality‑of‑life endpoints and HTA‑accepted comparators into clinical trial design from the outset, so regulatory and payer dossiers are built in parallel rather than in sequence
- Transform how your organisation generates pipeline evidence by embedding the payer perspective at every clinical governance gate, ensuring that what satisfies a regulatory authority and what secures formulary inclusion are treated as a single unified standard rather than competing priorities
Â
Gerardo Martinez, Senior Director, Global Market Access - Pipeline (Immunology & Rare Disease), CSL
Moderator: Jonathan Elliott, Director of Content Development, Thomson Reuters
- Establish market access as a core strategic function by building cross-functional bridges between pre-launch planning and post-launch execution, ensuring pricing strategies align with clinical and commercial objectives from day one
- Leverage increasing EU collaboration to navigate multi-country pricing and reimbursement pathways, sharing intelligence on reference pricing dynamics and coordinating submission strategies to optimise access timelines across markets
Â
Michela Pantaleoni, Chief Market Access Officer, Napo Therapeutics
Keir Woods, VP, Global Value Demonstration, Market Access & Pricing (GVAP) - Oncology, Merck
Eirini Palaka, Business Unit Head Oncology, Ipsen
Moderator: Catarina Costa-Pinheiro, Head of Global Pricing, Ferrer
- Reshape operating models and commercial decision making by leveraging data, technology, and AI to drive strategic agility across in market brands
- Evolve commercial models for established brands to protect value and improve efficiency in dynamic market conditions
- Scale impact and optimise resource allocation through flexible outsourcing commercialisation approaches informed by real time data and peer insights
Â
Brian Burgess, Director, International Business Development & Brand Outsourcing, IQVIA
Thomas Steffen, Principal, Strategy Consulting, IQVIA
Martin Bate, Head of HCP Engagement, IQVIA
At last year’s event, we introduced a bold blueprint for rewiring customer engagement with AI - a framework that illustrated how segmentation, targeting, omnichannel activation, content supply, and field execution could operate as a connected commercial and medical engagement ecosystem. This year, we shift from vision to reality, examining what has changed in the market, where organizations have made meaningful progress, where adoption has slowed, and what must evolve to unlock scaled, sustainable adoption and value. The workshop will:
- Explore advances emerging across areas like AI‑enabled and agentic sales operations
- Examine modernising end‑to‑end marketing and content supply
- Provide a practical view of how to evolve your field, marketing, and analytics capabilities in the year ahead
Priya Arora, EMEA Commercial AI and Data Lead, Deloitte
- An exclusive preview of new research will guide facilitated problem-solving that identifies where momentum breaks down and where to deploy practical solutions
- Accelerate execution by co-creating a Change Action Framework that prioritises CX challenges and aligns stakeholders on immediate next steps
- Identify measurements that capture true investment value and demonstrate impact across customer engagement initiatives
Dirk Szynka, Vice President Customer Experience, Inizio Engage International
Steph Plowright, Director of Strategy & Innovation, Nazaré
Greg Draper, Commercial Operations Director, Inizio Engage
This session is designed as an interactive experience, showing how teams can harness HCP behavioral intelligence via Inizio Evoke’s datalake in real time to sharpen targeting and drive activation.
Â
Using Predictevâ„¢, our live intelligence platform, attendees will be able to ask direct questions and see immediate answers on HCP prescribing behaviors, emerging patient segments, and growth opportunities, bringing data to life in the moment.
Â
Built on 75+ million hours of behavioral data, the platform surfaces audience mindsets, engagement triggers, and investment optimization opportunities across the treatment journey, enabling faster decisions, sharper targeting, and more confident investment decisions.
Â
Niklas Ekman, Practice Lead, Product, Inizio Evoke
- Share common challenges in evidence planning and execution in today’s multi-market, multi-audience environment
- Examine industry readiness to move beyond static evidence plans and scale the effective use of digital and intelligent tools across functions & teams
- Explore how evidence strategies can be designed for uncertainty, including evolving TPPs, adaptable scientific and value narratives, and multiple HTA and access scenarios across markets
Gavin J. Outteridge, General Manager, Arysana
From AI Experiments to Commercial Impact: Building a Governed Agentic Platform That Accelerates Time from R&D to Product Launch
AI pilots are multiplying across pharma. Few are scaling. Even fewer are accelerating launch performance. Many organizations are layering AI onto fragmented systems, creating more noise and not better execution. This workshop will explore how pharmas can move from isolated AI experiments to a governed agentic commercial platform built for highly-regulated environments:
- Connect agent workflows to the KPIs that matter compressing timelines across the entire pharma value chain and turning operational gains into accelerated market transformation
- Build a self-improving platform where engagement data and user behaviour signals feed back into agent policies and targeting models — so every product development and launch makes the next one faster and smarter
- Embed governance as an accelerant, leaving with a practical human-in-the-loop framework that creates auditable, continuously improving value chain operations without sacrificing speed
Rohit Dayama, Global Client Partner & Life Sciences Market Lead, Cognizant
Vishal Mehta, Global Head of Life Sciences, ServiceNow
• Co-design frameworks that give patient advocates and patients defined decision-making roles — not just advisory ones — across digital patient experience design, PSP development, and evidence generation, ensuring the patient voice shapes strategy rather than validates it after the fact
• Build transparent partnerships and establish clean guidelines that allow pharma executives and patient advocates to demonstrate impact to their respective stakeholders – and to each other
Moderator: Mark Duman, Patient Engagement Pioneer, MD Healthcare
- Expose real launch blockers using your own pharma use cases - not hypotheticals
- Break cross‑functional silos fast by aligning medical, commercial and market access around shared AI insights
- Shape AI‑powered launch moves that elevate HCP engagement and streamline compliant execution
- Create a standout concept that accelerates brand impact and is ready to socialize with your teams
Krystian Jablonski, Director, Data & AI Strategic Solutions and Poland Site Leader, Lingaro
Ivanka Vankova, Life Sciences Lead, Commercial Analytics, Lingaro
Question the foundations. Accelerate what matters. Shape a future of work that works for everyone
- Drive sustainable transformation by establishing identity, confidence and psychological safety as core infrastructure for AI adoption
- Deliver equitable outcomes by proactively dismantling bias in AI design and embedding inclusion as a strategic imperative
- Accelerate organization-wide capability by cultivating leadership practices that inspire experimentation
Dagmar Albers, VP EMEA, Healthcare Businesswomen's Association
Sarah Dancy Blackburn, Director of Value EMEA, Healthcare Businesswomen's Association
- Deploy digital pathways, wearables, and AI driven adherence platforms to enable direct, data powered patient engagement with measurable outcomes
- Accelerate therapy initiation and improve persistency by designing intelligent DTP ecosystems that balance access, trust, and adherence impact
- Generate actionable real world insights through direct patient engagement that informs evidence strategies and optimizes treatment delivery
Â
Shayma Ali, VP, Patient Engagement & Support Services, IQVIA
Jara Soltero, Senior Director, Global Lead for Patient Offerings & Innovation, IQVIA
Nagore Fernandez-Dominguez, Director, Integrated Solutions, Patient Engagement & Support , IQVIA
- Walk through real omnichannel journey maps anchored at congress including the booth interaction, the symposium Q&A, the KOL side conversation and pinpoint exactly where the intelligence signal dies before it reaches your CRM, your rep, or your next campaign brief.
- Diagnose the gap together: Using live examples from your own commercial models, the group pressure-tests congress identity resolution, data flow, and field activation to surface what is actually lost between the congress floor and commercial action.
- Co-create the fix in the room: Leave with a peer-designed blueprint for turning congress into a live intelligence engine resolving HCP signals to CRM records, triggering field follow-up, and feeding omnichannel orchestration in real time.
*Please bring your laptop, this is a practical and interactive session
Â
Pierre Metrailler, CEO, Onomi
- Gain insight into where AI tools for life sciences are heading, directly from those researching and building them
- Share learnings from AI implementations across pharma companies, with concrete examples from peers
- Co-develop a future-proof evaluation framework for AI tools to enable confident strategic decisions regarding new AI technology
Â
Jungwon Byun, Co-founder, Elicit
Sheena Pulapaka, Lead, Strategic Accounts, Elicit
James Brady, Head of Engineering, Elicit
Harry Johnson, EMEA Commercial Lead, Elicit
- As IRA negotiations, MFN pricing dynamics, and EU Joint Clinical Assessment requirements continue to shift the access landscape, how should launch timelines be prepared to ensure optimal time to market?
- If your last launch were stress-tested against today's geopolitical and regulatory environment, what would fail first (the strategy stage, the evidence generation stage, or at the point of local affiliate execution?
Pippa Postins, Global Head of Commercial Marketing, Global Pharma Strategy, Roche
Join a high-energy, hands-on AI Agents Hackathon and learn how to turn everyday tasks into autonomous workflows that work alongside your teams. Discover how commercial can elevate HCP engagement, medical can unlock actionable scientific insights, and clinical can accelerate site activation—while improving patient access and overall experience.
• Build your own: Collaborate to design an agent aligned to a real business challenge using a proven-and-tested approach.
• Leave with a blueprint: Walk away with a clear, scalable approach to launching and growing your agentic strategy.
Â
Ihab Fakhouri, HLS GTM Lead, Salesforce
Zoe MacKinnon, Solution Leader, Patient Services, Salesforce
Venkat Swaminathan, Pharma Account Executive, Salesforce
Tom Smith, Vice President - Life Sciences, Salesforce
Anne Schaible, Regional VP Pharma & Healthcare, Salesforce
